What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and ...

周五，BMO Capital Markets调整了对诺和诺德公司（NYSE:NVO）股票的目标价，将其从156.00美元下调至105.00美元。尽管目标价大幅下调，但该公司仍维持对这家医疗保健公司股票的"优于大市"评级。

CagriSema, a drug that Novo had hoped would become the next generation weight-loss aid, failed to meet expectations in ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out ...